Spectralink Corp (MM) News - SLNK

Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration

Silence Therapeutics plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA...

Silence Therapeutics to Present at 21st Annual Needham Virtual Healthcare Conference

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short...

Silence Therapeutics Announces Publication in the Journal of the American Medical Association Highlighting Results From SLN360 Phase 1 Study in Healthy Adults With High Lipoprotein(a)

– Results were simultaneously presented today in a late breaker at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22...

Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting

– SLN360 reduced Lp(a) – a key genetic risk factor for heart disease - by up to 98% with reductions of up to 81% persisting at 150 days –...

Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501

Silence to receive $3 million research milestone payment from Mallinckrodt Phase 1 study expected to begin in the first half of 2022 Silence...

Silence Therapeutics Reports Fourth Quarter and Full Year 2021 Results

– Positive SLN360 data to be presented in late breaker at the American College of Cardiology (ACC) Annual Meeting on April 3, 2022 – SLN124...

Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 17, 2022

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short...

Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer

Mark Rothera steps down as President and CEO Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the...

Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)

SLN360, an investigational siRNA to reduce risk of Lp(a)-mediated cardiovascular disease, was safe and well tolerated in the study SLN360...

Silence Therapeutics Announces SLN360 Phase 1 Data Accepted for Late-Breaking Presentation at the American College of Cardiology (ACC) Annual Scientific Session and Expo

Data to be presented by Professor of Cardiovascular Medicine at the Cleveland Clinic, Steven Nissen, MD, on Sunday April 3, 2022 Silence...

Silence Therapeutics’ Head of Molecular Design Dr. Marie Wikström Lindholm Appointed to Oligonucleotide Therapeutics Society Board of Directors

Silence Therapeutics plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short...

Polycom and SpectraLink Announce Expiration of Hart-Scott-Rodino Waiting Period for the Pending Acquisition of SpectraLink by Po

PLEASANTON, Calif. and BOULDER, Colo., March 12 /PRNewswire-FirstCall/ -- Polycom, Inc. (NASDAQ:PLCM) and SpectraLink Corporation (NASDAQ:SLNK...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Spectralink Corp (MM) (SLNK)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

SLNK News

Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration

Silence Therapeutics to Present at 21st Annual Needham Virtual Healthcare Conference

Silence Therapeutics Announces Publication in the Journal of the American Medical Association Highlighting Results From SLN360 Phase 1 Study in Healthy Adults With High Lipoprotein(a)

Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting

Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501

Silence Therapeutics Reports Fourth Quarter and Full Year 2021 Results

Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 17, 2022

Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer

Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)

Silence Therapeutics Announces SLN360 Phase 1 Data Accepted for Late-Breaking Presentation at the American College of Cardiology (ACC) Annual Scientific Session and Expo

Silence Therapeutics’ Head of Molecular Design Dr. Marie Wikström Lindholm Appointed to Oligonucleotide Therapeutics Society Board of Directors

Polycom Completes SpectraLink Acquisition

Polycom Announces Results of SpectraLink Tender Offer and Commences Subsequent Offering Period

SpectraLink Expands IP Telephony Support Through Digium|Asterisk Interoperability Partnership

Polycom and SpectraLink Announce Expiration of Hart-Scott-Rodino Waiting Period for the Pending Acquisition of SpectraLink by Po

SLNK Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Spectralink Corp (MM) (SLNK) News

Spectralink Corp (MM) (SLNK)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

SLNK News

Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration

Silence Therapeutics to Present at 21st Annual Needham Virtual Healthcare Conference

Silence Therapeutics Announces Publication in the Journal of the American Medical Association Highlighting Results From SLN360 Phase 1 Study in Healthy Adults With High Lipoprotein(a)

Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting

Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501

Silence Therapeutics Reports Fourth Quarter and Full Year 2021 Results

Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 17, 2022

Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer

Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)

Silence Therapeutics Announces SLN360 Phase 1 Data Accepted for Late-Breaking Presentation at the American College of Cardiology (ACC) Annual Scientific Session and Expo

Silence Therapeutics’ Head of Molecular Design Dr. Marie Wikström Lindholm Appointed to Oligonucleotide Therapeutics Society Board of Directors

Polycom Completes SpectraLink Acquisition

Polycom Announces Results of SpectraLink Tender Offer and Commences Subsequent Offering Period

SpectraLink Expands IP Telephony Support Through Digium|Asterisk Interoperability Partnership

Polycom and SpectraLink Announce Expiration of Hart-Scott-Rodino Waiting Period for the Pending Acquisition of SpectraLink by Po

SLNK Discussion

Your Recent History